Different GLP-1 medications, and different doses of the same medication, produce measurably different results across heart and metabolic health markers, according to an analysis pooling 19 randomized controlled trials involving 13,117 adults with overweight or obesity.
The finding is being framed as a step toward personalized obesity treatment. That framing is reasonable, but it needs a boundary: the analysis does not produce a validated tool for choosing a medication for an individual patient, and it does not change current prescribing guidance.
For the growing number of Americans taking these drugs, the practical takeaway is narrower and more useful than the headline. If your reason for taking a GLP-1 is not only weight but also blood pressure, blood sugar or cholesterol, the specific drug and dose may matter more than has generally been assumed, and that is worth raising with a prescriber.
The Ranking System the Researchers Built
The study, published in Diabetes, Obesity and Metabolism, was conducted by researchers at the University of Pennsylvania with colleagues at Yale School of Medicine and UT Southwestern Medical Center.
Rather than compare drugs on weight loss alone, the team created a composite measure called the Cardiometabolic Efficacy Index, a ranking-based score from 0 to 1 that summarizes performance across seven endpoints: percentage of total body weight lost, triglycerides, HDL cholesterol, LDL cholesterol, waist circumference, HbA1c and systolic blood pressure.
Higher doses generally scored higher. According to the published abstract, semaglutide at 7.2 mg achieved the top index score of 0.86, followed by orforglipron at 36 mg at 0.68 and semaglutide at 2.4 mg at 0.66. All three produced placebo-adjusted weight reductions of at least 10 percent. Rankings were broadly consistent whether or not participants had type 2 diabetes.
The differences between agents were not uniform across measures. As the full text sets out, orforglipron ranked strongest for blood sugar control, HDL cholesterol and systolic blood pressure, while semaglutide showed the greatest effects on LDL cholesterol, total body weight and waist circumference.
MedicalDaily Evidence Check
This is a systematic review and network meta-analysis, meaning it pools published randomized trials and compares treatments indirectly rather than testing them head-to-head in a single study. Nineteen trials with 13,117 participants were included, and the searches covered literature from early 2014 through November 2025. Network meta-analysis is a well-accepted method, but indirect comparisons carry more uncertainty than direct ones, and differences in how the underlying trials were designed and who they enrolled can influence the rankings.
Several limitations are material. The analysis deliberately included only GLP-1 receptor mono-agonists, meaning semaglutide, liraglutide, and orforglipron. Tirzepatide and other dual or triple incretin agonists were excluded for mechanistic consistency, so the results say nothing about how those agents would rank. The Cardiometabolic Efficacy Index is a new composite developed by the authors for this analysis, not an externally validated clinical decision tool, and a composite score can obscure the fact that a drug ranking well overall might rank poorly on the one measure a given patient cares most about. Availability also varies by agent, formulation, and dose.
Current medical guidance has not changed as a result of this analysis. In the university's announcement, co-author Yuan Lu said that "as obesity treatment becomes increasingly personalized, clinicians are often choosing among several highly effective therapies rather than deciding whether to treat at all," and that considering blood pressure, cholesterol and glucose control together could help align treatment with an individual profile. That is a hypothesis worth testing, not a prescribing algorithm.
One editorial note on timing: this paper appeared online in the journal in the spring, with the university announcement circulating in late July. It is newly promoted rather than newly published.
Who This Actually Applies To
The trials pooled here enrolled adults with overweight or obesity, with and without type 2 diabetes. Findings do not extend to adolescents, to people taking these medications for other indications, or to anyone using compounded or unapproved versions.
The people for whom this is most relevant are patients who have more than one cardiometabolic problem at once, which describes a large share of GLP-1 users. Someone whose main clinical concern is elevated HbA1c and blood pressure faces a different calculus than someone whose primary goal is weight reduction and waist circumference, and the analysis suggests those goals may not point to the same agent or dose.
It is equally relevant to note what usually decides the question in practice. Insurance formularies, prior authorization requirements, out-of-pocket cost, tolerability and supply availability drive most real-world prescribing decisions, and no ranking index overrides a plan that covers only one agent.
Questions Worth Bringing to a Prescriber
Nobody should switch medications, change a dose or stop treatment based on this analysis. Dose escalation with GLP-1 medications is deliberate and gradual because side effects including nausea, vomiting, and diarrhea are common, and higher doses are not appropriate or tolerable for everyone.
A more productive conversation covers what you are treating beyond the scale. Ask which cardiometabolic markers your clinician is tracking, whether your current agent and dose align with those goals, and what your plan actually covers. If cost is the obstacle, ask about manufacturer assistance programs and about whether an oral option is covered when an injectable is not.
The researchers noted that oral GLP-1 therapies are emerging as competitive options that could improve access and adherence, and should continue to be studied. Head-to-head randomized trials comparing agents directly on cardiometabolic outcomes, and analyses that include dual and triple agonists, are the evidence that would move this from an interesting signal to a clinical tool. MedicalDaily will report those results when they appear.
Frequently Asked Questions
What did the analysis actually find? That GLP-1 mono-agonists differ from one another, and across doses, in how they affect seven heart and metabolic measures, with higher doses generally scoring better on a composite index.
Does this mean one drug is best? No. Different agents ranked highest on different individual measures, and the researchers framed the result as supporting individualized choice rather than a single winner.
Was tirzepatide included? No. The analysis covered GLP-1 mono-agonists only. Dual and triple incretin agonists were excluded.
Is the Cardiometabolic Efficacy Index used in clinical practice? No. It is a research measure the authors developed for this analysis and has not been validated as a tool for individual treatment decisions.
Should I ask to switch medications? Not on the basis of this study. Discuss your specific treatment goals and coverage with a prescriber before changing anything.
Do these findings apply to compounded GLP-1 products? No. The trials examined regulated products at studied doses. Compounded or unapproved versions were not evaluated and carry separate safety concerns.
What research would answer the open questions? Direct head-to-head randomized trials comparing agents on cardiometabolic outcomes, and analyses that include dual and triple agonists.
